Navigation Links
Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
Date:2/6/2008

Effort is Launched With UC Davis Collaboration

RANCHO CORDOVA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury, today announced a regenerative medicine initiative in the veterinary market.

The Company has created a wholly-owned subsidiary, Vantus, Inc., a veterinary stem cell laboratory services company. The Company is in the process of completing a research collaboration with the Center for Equine Health and Stem Cell Regenerative Medicine Group at the University of California, Davis, School of Veterinary Medicine.

Under the collaboration, the Company's MarrowXpress(TM) System and BioArchive(R) System will be used for the processing and cryogenic storage of equine stem cells from cell rich sources, including fetal tissue and fluids during foaling, and bone marrow from yearlings and adults. The stem cells will be used in therapeutic treatment of orthopedic injuries in the performance equine market including Thoroughbreds, American Quarter Horses, and Arabians. The Company is currently refining collection and processing methodologies at large breeder farms in California, and expects to be in operation commencing with the 2009 foaling season, which begins in January of next year.

"The creation of Vantus, Inc. is a major milestone in our regenerative medicine diversification strategy that we began implementing several months ago. This program leverages the expertise and world renowned reputation of the UC Davis organization in animal research and our industry leading stem cell processing and storage technologies," noted Dr. William Osgood, Chief
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ThermoGenesis Corp. Reports First Quarter 2008 Results
2. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
3. Zipfizz(R) Announces Expanded Distribution
4. Mangrove Announces Health Savings Account (HSA) and Health Reimbursement Account (HRA) Product Launches
5. Senetek PLC Announces Launch of New Website
6. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
7. Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008
8. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
9. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
10. The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application
11. Thermage, Inc. Announces Fourth Quarter 2007 Results Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 03, 2015 Johnson & Johnson and ... million to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... company allegedly used to market the antipsychotic drug. ... that the Arkansas Attorney General moved to dismiss the ... The Risperdal settlement amounts to just a fraction of ...
(Date:6/3/2015)... June 03, 2015 “ Harmony ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... that wants to improve some aspect of their life. , ... only for people with difficulties in their life. However, hypnotherapy ...
(Date:6/3/2015)... 2015 Follow us on LinkedIn ... revolutionized disease treatment on account of their better mode ... such as rheumatoid arthritis. The industry is expected to ... small molecule drugs to biopharmaceuticals over the coming years. ... and gene therapies, and recombinant proteins has attracted industry ...
(Date:6/3/2015)... On the heels of a report predicting ... 2020 ( click here to review news coverage about ... Baltimore has the talent to become a world-leading center ... and other biological data are collected and analyzed to help ... all the elements of a perfect storm for bioinformatics leadership,” ...
(Date:6/3/2015)... Dr. Steven Reisman, a nationally recognized cardiologist and ... ) located in NYC, announced today the expansion of same ... most cases, depending on the level of care a patient ... will be seen by a cardiologist that same day. , ... to ensure that people who have an urgent need to ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2
... says , WEDNESDAY, Jan. 20 (HealthDay News) -- Heart and ... mild cases of chronic lung disease affect the heart,s ability ... that a larger subset of heart failure may be due ... professor of medicine and epidemiology at Columbia University Medical Center ...
... 3 fewer grams a day slashed heart disease, death rates ... just 3 grams a day -- the equivalent of half a ... death in U.S. adults, researchers claim. , According to the authors ... New England Journal of Medicine , the projected reductions would ...
... , WASHINGTON , Jan. 20 ... Tony Perkins released the following statement regarding the ... "For a Senate seat considered to be in the left-hand column ... nearly revolutionary. President Obama,s desperate visit to the Bay State ...
... Implications of Federal Medicare Cuts Require Careful Scrutiny and ... , AUSTIN, Texas , Jan. 20 ... Tim Graves , today expressed concern about the growing cumulative ... preserve and protect Texas, most vulnerable nursing home ...
... researchers at Rush University Medical Center have found three ... to social rejection. The studies are a crucial step ... for social-emotional learning difficulties. The results from the studies ... and Adolescent Psychology . Findings from the ...
... in human cells has singled out a molecule that ... produce an allergic response. The signaling molecule, called thymic ... allergic diseases such as asthma, atopic dermatitis (eczema) and ... Liu, M.D., Ph.D., at the University of Texas M.D. ...
Cached Medicine News:Health News:Even Mild Lung Disease Affects the Heart 2Health News:Small Cuts in Salt Intake Spur Big Drops in Heart Trouble 2Health News:Small Cuts in Salt Intake Spur Big Drops in Heart Trouble 3Health News:FRC: Mass Election Results a Near Revolutionary Rejection of President Obama's Leftist Agenda 2Health News:Texas Health Care Association: Meeting Texas Seniors' Ongoing Care Needs Threatened by Looming State, Federal Funding Threats 2Health News:3 key factors to help children avoid social rejection identified 2
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "The Future of Pharmaceutical Outsourcing" ... they are in a desperate need to develop ... cost, drug companies have been increasingly utilizing external ... productivity while constantly streamlining their internal operation. Their ...
(Date:6/3/2015)... SHANGHAI , June 3, 2015 MEDTEC China South ... an extension of MEDTEC China 2015, MEDTEC China South has ... attributes, standing out as a key event for the medical ... After many years of challenges, this year marks the successful return ... 10 years after the event first debuted there in 2005. ...
(Date:6/3/2015)... , June 3, 2015 Genoa ... Pharmaceuticals, Inc., bringing together two pharmacy organizations with proven ... illness. Both companies have strong reputations for outstanding customer ... Genoa is the ... health community and those affiliated with managing the cost ...
Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3Genoa, a QoL Healthcare Company Acquires Northeast Pharmaceuticals, Inc. 2
... , MORRISTOWN, N.J. , March 11 ... today announced the U.S. Food and Drug Administration (FDA) ... suspension), a new twice-yearly formulation of TRELSTAR®, a proven, ... With an anticipated May launch, TRELSTAR® 22.5 mg is ...
... , THOUSAND OAKS, Calif. , March 11 ... has received a US Patent Office Notice of Allowance ... expressing, secreting, and purifying the NELL-1 sequence of the ... a Chinese hamster ovary (CHO) cell. This patent continues ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 2Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 3
... The Hoffmann® II Compact™ Upper extremity fixator ... of the distal radius by allowing independent ... One of the main goals has been ... providing total versatility and ease of use. ...
The Small External Fixator has straight or angled frames, independent pin placement, and combines easily with Large and Medium External Fixator frames....
... Fixator is now available in a convenient, ... instrumentation. The surgical technique is printed on ... , ,This fixator allows the surgeon to ... multipaner adjustments in the frame via joints ...
... Fixation System for distal radius fractures allows ... length and rotation. The unique wrist lock ... into extension without losing fracture reduction. Post-op ... the surgeons office. Priced competitively and sold ...
Medicine Products: